Trial of ONC-PluReceptor NK Cells for B-cell Non-Hodgkin Lymphoma
This study is testing a new treatment for people with B-cell Non-Hodgkin Lymphoma that has come back (recurrent) or hasn't responded to other treatments (refractory). The treatment involves special immune cells called ONC-PluReceptor NK cells, given by injection, along with two other medicines called epcoritamab and tafasitamab. Researchers want to see if this combination can help control the lymphoma and how safe it is. You might be able to join if you are 18-80 years old, have B-cell Non-Hodgkin Lymphoma that has failed at least two prior treatments or a stem cell transplant, and your tumor shows specific markers (CD19 or CD20). The study aims to enroll 30 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored throughout the study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Yago Nieto, MD,PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0